Corpus Intelligence IC Memo — UNIVERSITY OF MISSISSIPPI MEDICAL 2026-04-26 03:43 UTC
IC Memo — UNIVERSITY OF MISSISSIPPI MEDICAL
Investment Committee Memorandum | MS | 745 beds | Grade C | EBITDA uplift $77.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UNIVERSITY OF MISSISSIPPI MEDICAL

CCN 250001 | HINDS, MS | 745 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

UNIVERSITY OF MISSISSIPPI MEDICAL is a 745-bed large academic medical center in HINDS, MS with $1.06B in net patient revenue and a -3.0% operating margin. The hospital serves a payer mix of 16.8% Medicare, 38.7% Medicaid, and 44.4% commercial.

Thesis: Undervalued. Our ML models identify $77.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -3.0% to 4.4% (+736bps).

Net Revenue HCRIS$1.06B
Current EBITDA COMPUTED$-31.8M
Operating Margin COMPUTED-3.0%
Occupancy HCRIS81.6%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS26.6%
Distress Probability ML50.4%

2. Market Context & Competitive Position

110
MS Hospitals
-12.5%
State Median Margin
475
Comparable Hospitals

MS has 110 Medicare-certified hospitals with a median operating margin of -12.5%. The target's margin of -3.0% places it above the state median. Among 475 size-comparable peers (372-1490 beds), the median margin is -4.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (372-1490), prioritizing same-state peers. 475 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UNIVERSITY OF MISSISSIPPI MEDI (Target)MS745$1.06B-3.0%
ST. LUKES HOSPITALPA633$8.94B87.9%
STANFORD HEALTH CARECA657$6.76B3.7%
CLEVELAND CLINIC HOSPITALOH1326$6.38B-17.7%
VANDERBILT UNIVERSITY MEDICAL TN1084$5.44B-15.9%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $77.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$22.2M+210bp18mo
Cost to Collect4.5%2.5%$21.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$20.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$12.9M+122bp9mo
Clean Claim Rate88.0%96.0%$677K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$22.2M
Cost to Collect
$21.2M
Denial Rate Reduction
$20.9M
A/R Days Reduction
$12.9M
Clean Claim Rate
$677K
Total EBITDA Uplift$77.9M
Current EBITDA$-31.8M
+ RCM Uplift+$77.9M
Pro Forma EBITDA$46.1M
Current Margin-3.0%
Pro Forma Margin4.4%
WC Released (1x)$40.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-48.9M$569.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-48.9M$610.0M0.00x-100.0%
Bull Case9.0x11.0x$-44.0M$851.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-44.0M$915.4M0.00x-100.0%
Bear Case11.0x10.0x$-53.8M$195.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-53.8M$197.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (38.7%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 50.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 475 hospitals with 372-1490 beds
  • Same-state prioritization (n=5)
  • Comp margins: P25=-15.0% / P50=-4.6% / P75=4.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.